ClinicalTrials.gg
RecruitingNCT01913132Updated Nov 19, 2026

PICO Above Incisions After Vascular Surgery

An interventional study of Negative pressure wound therapy with PICO (Smith & Nephew) in Wound and Infection, sponsored by Stefan Acosta. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Stefan Acosta · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2013; still recruiting 13 years later.
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
644
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The wound infection rate in the groin after vascular surgery has been denoted to be high since the wound surveillance register started in 2005. The current wound infection rate based on a validation study was 22.9% (24/105 patients with groin incision(s) between 1 March to 30 June in 2012). This randomized controlled trial aims to evaluate if negative pressure wound therapy on closed inguinal incisions (INPWT) after vascular surgical procedures can reduce the risk for surgical site infections and other wound complications.

Read the detailed description

As published in the study´s rational and design paper (DOI: 10.4236/ss.2015.612080), we conducted a reanalysis of the material that the original power calculation was based on and included elective cases only which led to a slightly different number of cases needed. Furthermore, it became clear that there were big differences in the infection rates of EVAR (endovascular aortic repair) and open vascular procedures and therefore the need to split the study into two arms, an EVAR arm and an OPEN arm.

To prove a significant effect of the treatment intervention in the EVAR arm with a wound infection rate reduction from previously 4.4% to 1%, 80% power, 5% significance level and Including a margin for loss to follow-up, the EVAR arm requires 497 inguinal incisions. Assuming a surgical site infection rate reduction from 30% to 10% in the OPEN arm of the study, 80% power and 5% significance level, a total of 147 inguinal incisions is required.

We conducted an unannounced interim analysis for a conference presentation that was conducted by the study's principal investigators Stefan Acosta and Julien Hasselmann. Staff in charge of the day-to-day activities of the trial were not involved or actively informed of this. We believe that using an objective wound assessment tool (ASEPSIS score) minimizes any potential bias associated with the interim analysis.

Since the vascular center Malmö has started using closure-devices for almost all EVAR cases and thereby creating virtually no wounds to assess, we have started a multi center extension of the EVAR arm to Örebro University Hospital to be able to include the outstanding cases.

FUNDING

The trial has been funded by public Swedish funds stemming from the Southmost region in Sweden (Region Skåne), the Skåne University Hospital and the Hulda Almroth foundation since 2015 and adds up to a total of 2.81 million SEK (about 311,000 USD). In addition the research group received an unrestricted unconditional research grant of 15,550 USD and a donation of 100 PICO dressing kits from Smith and Nephew in 2013.

ALF (Agreement on medical education and research) funding has been granted for the time period 2019 - 2022 but has not yet been defined monetarily.

02

Conditions studied

  • Wound
  • Infection

Keywords

  • Negative pressure wound therapy
  • Vascular Surgery
  • Inguinal incisions
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's planned enrollment of 644 is above the median of 70 across 1,426 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

This is the only study on the registry with Stefan Acosta as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years of age and above
  • Elective vascular surgery
  • Inguinal incision (transverse or longitudinal)
  • Capable of understanding the study information and giving written

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery
  • Ongoing infection in inguinal area
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
644 participants (estimated)

Study arms

  • No intervention
    Standard wound dressing OPEN

    Standard wound dressing

  • Experimental
    PICO dressing OPEN

    Negative pressure wound therapy with PICO (Smith \& Nephew)

    Device: Negative pressure wound therapy with PICO (Smith & Nephew)

  • No intervention
    Standard dressing EVAR

    Standard wound dressing

  • Experimental
    PICO dressing EVAR

    Negative pressure wound therapy with PICO (Smith \& Nephew)

    Device: Negative pressure wound therapy with PICO (Smith & Nephew)

Interventions

  • DeviceNegative pressure wound therapy with PICO (Smith & Nephew)

    Negative wound pressure therapy

06

What researchers measure

Primary outcomes

  1. Wound infection rate

    ASEPSIS (Additional treatment, the presence of Serous discharge, Erythema, Purulent exudate, and Separation of the Deep tissues, the isolation of bacteria, and the duration of inpatient stay) score. Min 0 p, max \> 40 p, higher values worse outcome

    Time frame: Wounds will be checked at 3 month follow-up

Secondary outcomes

  1. Overall Costs of treatment

    Systematic assessment of overall costs

    Time frame: Costs will be checked at 3 months of follow-up

07

Study locations

1 of 1 sites recruiting
  • Vascular Centre, Malmö, Skåne University Hospital
    Malmö, Sweden
    Recruiting
    • Stefan Acosta, MD PhD · Contact
08

References and documents

Publications

  • Hasselmann J, Bjork J, Svensson-Bjork R, Acosta S. Inguinal Vascular Surgical Wound Protection by Incisional Negative Pressure Wound Therapy: A Randomized Controlled Trial-INVIPS Trial. Ann Surg. 2020 Jan;271(1):48-53. doi: 10.1097/SLA.0000000000003364. PubMed 31283565 ↗
  • Correia RM, Nakano LC, Vasconcelos V, Cristino MA, Flumignan RL. Prevention of infection in peripheral arterial reconstruction of the lower limb. Cochrane Database Syst Rev. 2025 Oct 29;10(10):CD015022. doi: 10.1002/14651858.CD015022.pub2. PubMed 41159585 ↗
  • Rezk F, Astrand H, Svensson-Bjork R, Hasselmann J, Nyman J, Butt T, Bilos L, Pirouzram A, Acosta S. Multicenter parallel randomized trial evaluating incisional negative pressure wound therapy for the prevention of surgical site infection after lower extremity bypass. J Vasc Surg. 2024 Apr;79(4):931-940.e4. doi: 10.1016/j.jvs.2023.11.043. Epub 2023 Nov 30. PubMed 38042513 ↗
  • Svensson-Bjork R, Hasselmann J, Asciutto G, Zarrouk M, Bjork J, Bilos L, Pirouzram A, Acosta S. Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections Using Fascia Closure After EVAR-A Randomized Trial. World J Surg. 2022 Dec;46(12):3111-3120. doi: 10.1007/s00268-022-06740-5. Epub 2022 Oct 14. PubMed 36241857 ↗
  • Rezk F, Astrand H, Acosta S. Incisional negative pressure wound therapy for the prevention of surgical site infection after open lower limb revascularization - Rationale and design of a multi-center randomized controlled trial. Contemp Clin Trials Commun. 2019 Oct 14;16:100469. doi: 10.1016/j.conctc.2019.100469. eCollection 2019 Dec. PubMed 31701043 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2013 (actual). Primary completion is estimated for Dec 2027, 169 months after the start.

Of 546 non-industry interventional studies with no phase under Wounds and Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's planned 169 months is above that.

Counting every sponsor, half of 599 studies reached it within 24 months; a quarter within 9 and three quarters within 48.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2013
First posted
Jul 31, 2013
StartActual
Nov 2013
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2027
Nov 19, 2026
Study completion
Dec 2026→Dec 31, 2027
Nov 19, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 41159585 ↗
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 41159585 ↗
    Primary completion Dec 2026→Dec 2027
    Study completion Dec 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01913132
Lead sponsor
Stefan Acosta
Responsible party
Stefan Acosta (Professor, Skane University Hospital) — Sponsor-investigator
First posted
Jul 31, 2013
Start date
Nov 2013
Primary completion
Dec 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Stefan Acosta, MD PhD
Contact
stefan.acosta@med.lu.se
+4640331000
Stefan Acosta, MD PhD
principal investigator · Vascular Centre, Malmö, Skåne University Hospital
Julien Hasselmann, MD
principal investigator · Vascular Centre, Malmö, Skåne University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion